Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 3935-3942

  Sievers, Philipp ^a   Uhlmann, Lorenz ^a   Korkmaz Icöz, Sevil ^a   Fastner, Christian ^a   Bea, Florian ^a   Blessing, Erwin ^a   Katus, Hugo A ^a   Preusch, Michael R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Advanced atherosclerosis; ApoE; AT1 receptor blocker; Calcium channel antagonist; Inflammation; NF B

Indexed keywords

AMLODIPINE BESYLATE; APOLIPOPROTEIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLMESARTAN; AMLODIPINE PLUS OLMESARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRACHIOCEPHALIC TRUNK; CONTROLLED STUDY; DNA BINDING; FEMALE; MOUSE; NONHUMAN; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; GEL MOBILITY SHIFT ASSAY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

AMLODIPINE BESYLATE, OLMESARTAN MEDOXOMIL DRUG COMBINATION; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B;

EID: 84938332676     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S85203     Document Type: Article

References (29)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–325.
2. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38(6):1092–1104.
3. Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res. 2014;114(1):214–226.
4. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74(2):213–220.
5. Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19(9):1166–1172.
6. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005;25(5):904–914.
7. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204–212.
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(18):1685–1695.
9. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410–1422.
10. Cristofori P, Lanzoni A, Quartaroli M, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000;18(10):1429–1436.
11. Shimada K, Murayama T, Yokode M, Kita T, Fujita M, Kishimoto C. Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production. Nutr Metab Cardiovasc Dis. 2011;21(9):672–678.
12. Takaya T, Kawashima S, Shinohara M, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186(2):402–410.
13. Suzuki J, Iwai M, Li Z, et al. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens. 2005;23(7):1383–1389.
14. Yoshii T, Iwai M, Li Z, et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res. 2006;29(6):457–466.
15. Noda K, Hosoya M, Nakajima S, Ohashi J, Fukumoto Y, Shimokawa H. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice. Tohoku J Exp Med. 2012;228(4):305–315.
16. Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N. Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res. 2009;50 Suppl:S178–182.
17. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov. 2011;10(5):365–376.
18. Movat HZ. Demonstration of all connective tissue elements in a single section; pentachrome stains. AMA Arch Pathol. 1955;60(3): 289–295.
19. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol. 2000;20(12):2587–2592.
20. Johnson JL, Jackson CL. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis. 2001;154(2): 399–406.
21. Williams H, Johnson JL, Carson KG, Jackson CL. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2002;22(5):788–792.
22. Rosenfeld ME, Averill MM, Bennett BJ, Schwartz SM. Progression and disruption of advanced atherosclerotic plaques in murine models. Curr Drug Targets. 2008;9(3):210–216.
23. Ylä-Herttuala S, Bentzon JF, Daemen M, et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost. 2011;106(1):1–19.
24. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res. 2002;53(2):313–325.
25. Madonna R, De Caterina R. Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease. Vascul Pharmacol. 2012;57(1):41–47.
26. Stellos K, Dimmeler S. Vascular microRNAs: from disease mechanisms to therapeutic targets. Circ Res. 2014;114(1):3–4.
27. Blessing E, Preusch M, Kranzhöfer R, et al. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis. 2008;199(2):295–303.
28. Esteban V, Lorenzo O, Rupérez M, et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol. 2004;15(6):1514–1529.
29. Cominacini L, Garbin U, Fratta Pasini A, et al. Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens. 1997;15(12 Pt 2):1633–1640.